Dataset Information


Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.

ABSTRACT: BACKGROUND:Truenat is a novel molecular assay that rapidly detects tuberculosis (TB) and rifampicin-resistance. Due to the portability of its battery-powered testing platform, it may be valuable in peripheral healthcare settings in India. METHODS:Using a microsimulation model, we compared four TB diagnostic strategies for HIV-negative adults with presumptive TB: (1) sputum smear microscopy in designated microscopy centers (DMCs) (SSM); (2) Xpert MTB/RIF in DMCs (Xpert); (3) Truenat in DMCs (Truenat DMC); and (4) Truenat for point-of-care testing in primary healthcare facilities (Truenat POC). We projected life expectancy, costs, incremental cost-effectiveness ratios (ICERs), and 5-year budget impact of deploying Truenat POC in India's public sector. We defined a strategy "cost-effective" if its ICER was


PROVIDER: S-EPMC6605662 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6370043 | BioStudies
| S-EPMC3517815 | BioStudies
2014-01-01 | S-EPMC4165752 | BioStudies
2020-01-01 | S-EPMC7302325 | BioStudies
2013-01-01 | S-EPMC3669338 | BioStudies
2013-01-01 | S-EPMC4133735 | BioStudies
2017-01-01 | S-EPMC5634708 | BioStudies
2019-01-01 | S-EPMC6597104 | BioStudies
2014-01-01 | S-EPMC3898963 | BioStudies
1000-01-01 | S-EPMC6094004 | BioStudies